merit flaw trial drug covid chinadaili com cn sign post gilead scienc headquart april foster citi california photo agenc scientist recent report mix clinic result close watch experiment covid drug remdesivir chines trial find signific benefit preliminari data unit state claim patient receiv drug seen improv expert world said studi merit flaw current clinic evid suggest remdesivir magic bullet assum media outlet research drug' efficaci effect necessari chines trial reach target enrol studi peer-review publish find taken grain salt said ad public rush dismiss endors drug thursday journal lancet publish peer-review result drug' clinic trial china led cao bin vice-presid china-japan friendship hospit studi base patient far intend sampl size case defici steep declin total number covid case china author said chines studi double-blind random control trial golden standard clinic research studi median number day clinic improv remdesivir group day significantli differ control group drug did significantli lower mortal rate patient test group moral rate percent control group percent group share similar ratio patient experienc advers effect percent percent test control group respect common advers event group constip low level albumin blood defici red blood cell patient test group drop studi effect respiratori failur compar dropout control group thursday cao said articl breath-circl chines media platform respiratori medic profession remdesivir did reach expect therapeut result studi drug proven gener safe studi underpow chines author caution read result suggest research especi regard explor drug' potenc earli treatment conjunct antivir treatment studi conduct nation institut allergi infecti diseas preliminari result said patient receiv remdesivir percent faster recoveri time control group accord inform releas nation institut health thursday median recoveri time day treat patient compar day control group result suggest slight decreas mortal rate percent group receiv drug versu percent control group studi began feb double-blind random control trial involv patient nih did releas inform advers effect dosag use experi promis releas comprehens peer-review data later report cao told chines media object speak chines trial rigor design admit difficult compar studi differ experi design endpoint criteria chines studi patient enrol day onset symptom avoid interfer treatment ensur accur result studi did requir accord nih addit criteria recoveri lenient studi cao said studi defin day recoveri day subject satisfi follow categori hospit requir supplement oxygen hospit limit activ hospit limit activ chines studi six-point scale rang clinic statu discharg hospit ventil intens care patient need extracorpor membran oxygen life support machin pump oxygen patient' blood outsid bodi clinic improv document patient' condit improv level scale remdesivir realli wonder cure shown obviou therapeut advantag compar control group cao told news outlet caixin comment publish lancet john norri professor medic statist trial methodolog univers edinburgh unit kingdom said chines clinic trial design result inconclus insuffici statist power trial just primari clinic outcom import data safeti viral load secondari outcom said stephen evan professor pharmacoepidemiolog london school hygien tropic medicin said studi featur encourag result assess see public outcom substanti evid remdesivir genuin benefit certainli dramat said